BioSpace News Archive

Candel Therapeutics, Inc. announced that Jason A. Amello, has been named as the Company’s Chief Financial Officer and Garrett Nichols, MD, MS, has been named as the Company’s Chief Medical Officer.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the addition of Mohammad K. Khan, M.D., Ph.D. to its Medical Advisory Board.

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held September 12–14, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in New York, NY.

Amolyt Pharma announced it will host a hybrid key opinion leader event on the Company’s potential hypoparathyroidism treatment, AZP-3601, on Monday, September 12, 2022, at 1:30 pm CT /2:30 pm ET in Austin, Texas.

Xenetic Biosciences, Inc. announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences in September:.

Baxter International Inc., a global medtech leader, reinforced its commitment to expand the pipeline of Black healthcare professionals through several programs that support Black students pursuing health and science degrees at Historically Black Colleges and Universities.

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.

Exscientia announced that Company management will participate in the following investor conferences in September.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that full results from the CONNECT1 study evaluating the ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and the Digihaler System in the management of asthma patients compared to standard of care (SoC) albuterol reliever therapy, were published online ahead of print in The Journal of Allergy and Clinical Immunology: In Practice.